Ergebnis der Suchanfrage nach Darmstadt

National Research Center for Applied Cybersecurity ATHENE

Severe Vulnerabilities Discovered in Software to Protect Internet Routing

National Research Center for Applied Cybersecurity ATHENE

Serious Vulnerability in the Internet Infrastructure / Fundamental design flaw in DNSSEC discovered

Plansecur KG

Lamia Messari-Becker is named “Thought Leader 2024“

Fraport AG

E-Project at Frankfurt Airport Using Charging Infrastructure Bidirectionally

Öko-Institut e.V.

Factsheets released on different project types in the carbon market

Joint press release by Oeko-Institut, CCQI and Foundation Development and Climate Alliance Berlin, 12 September 2023 Factsheets released on different project types in the carbon market To contribute to achieving the Paris Climate Agreement and the Sustainable Development Goals, carbon credits in the voluntary carbon market need to be of high quality. ...

Öko-Institut e.V.

The future of road freight transport is electric

Press release Freiburg/Berlin, 29 August 2023 The future of road freight transport is electric The availability of a broad-scale and well-performing charging network by 2035 offers potential to increase new registrations of battery electric trucks to 100 per cent. The key entry point for ensuring the market success of zero-emission drive technologies is ...

R-Biopharm AG

2

R-Biopharm AG announces personnel changes in the Board of Directors and restructuring

hubergroup Deutschland GmbH

4

Press Release - hubergroup to feature iray – its new UV flexo portfolio – at LMAI Conference 2023

Fraunhofer-Institut für Sichere Informationstechnologie SIT

AI against money laundering

Öko-Institut e.V.

New platform sheds light on the bioeconomy

Harnessing innovation to build a bio-based, climate-neutral and circular economy – that is the goal of Germany’s National Bioeconomy Strategy. But is Germany on track, and does development align with the overarching Sustainable Development Goals? Please excuse any double sendings Joint Press release Oeko-Institut and Symobio 2.0 Darmstadt, 18. April ...

R-Biopharm AG

Blood Donation Day at R-Biopharm: Employees Help Save Lives

R-Biopharm AG

Flu tests from R-Biopharm also detect new virus variants

benfovir AG

benfovir AG has reached another milestone by completing the first part of the Phase 1 trial testing transketolase inhibitor / benfo-oxythiamine (B-OT)

Darmstadt (ots) - benfovir AG, a German pharmaceutical company focused on developing small molecules against viral infections such as SARS-CoV-2, dengue and herpes virus, today announced that the first part of the Phase 1 clinical trial (BV-01-101/ EudraCT Number: 2021-005616-60.) designed to evaluate the safety, ...

Fraunhofer-Institut für Sichere Informationstechnologie SIT

Document protection with colorful barcode / Simple forgery protection for paper documents and PDFs – automated tamper control via app

Fraunhofer-Institut für Sichere Informationstechnologie SIT

Mechanism for Internet security broken

Technische Universität München

BMW CEO Oliver Zipse appointed honorary professor

TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Images: https://mediatum.ub.tum.de/1688517 NEWS RELEASE Oliver Zipse appointed honorary professor BMW CEO to lecture on the transformation of the automotive industry Oliver Zipse, the CEO of BMW AG, has been appointed to an honorary professorship at the Technical University of Munich (TUM). He ...

hubergroup Deutschland GmbH

5

Press Release - hubergroup Print Solutions relaunches UV flexo portfolio under the iray brand®

R-Biopharm AG

R-Biopharm starts commercialization of the fully automated RIDA®UNITY system for real-time PCR in molecular diagnostic laboratories

R-Biopharm AG

R-Biopharm is IVDR certified

Schoeller Allibert

2

Schoeller Allibert appoints Oliver Iltisberger as CEO

benfovir AG

benfovir Announces First Subjects Dosed in Phase 1 Clinical Trial of B-OT/ B-OT IS BEING DEVELOPED FOR THE TREATMENT OF VIRAL INFECTIONS

Darmstadt (ots) - benfovir AG has reached another major milestone by moving its first compound into clinical development with the start of a Phase 1 testing B-OT in healthy volunteers. benfovir AG, a German pharmaceutical biotechnology company focused on developing small molecules against viral infection such as ...

R-Biopharm AG

2

R-Biopharm acquires Australian lab equipment manufacturer and molecular biology multiplex specialist AusDiagnostics

R-Biopharm AG

R-Biopharm announces test to detect monkeypox virus

R-Biopharm AG

2

R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation